| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 121 | Biological material detecting articles of manufacture | US10002402 | 2001-10-25 | US06867052B2 | 2005-03-15 | Terri Lander; William T. Bodenhamer |
| The present invention relates to articles of manufacture inclusive of or in combination with a biological assay material, formed from a material capable of detecting and identifying the presence of one or more particular toxic substances, wherein said toxic substances may comprise a multiplicity of biological materials. | ||||||
| 122 | Extracellular matrix-binding proteins from Staphylococcus aureus | US10744672 | 2003-12-24 | US20040254354A1 | 2004-12-16 | Joseph M. Patti; Timothy J. Foster; Elisabet Josefsson; Deidre Ni Eidhin; Magnus A.O. Hook; Samuel E. Perkins |
| Isolated extracellular matrix-binding proteins, designated ClfB, SdrC, SdrD and SdrE, and their corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials. ClfB is a cell-wall associated protein having a predicted molecular weight of approximately 88 kDa and an apparent molecular weight of approximately 124 kDa, which binds both soluble and immobilized fibrinogen. ClfB binds both the alpha and beta chains of fibrinogen and acts as a clumping factor. SdrC, SdrD and SdrE are cell-wall associated proteins that exhibit cation-dependent ligand binding to the extracellular matrix. It has been discovered that in the A region of SdrC, SdrD, SdrE, ClfA and ClfB, there is a highly conserved amino acid sequence that can be used to derive a consensus motif of TYTFTDYVD. | ||||||
| 123 | Method and apparatus for detection of multiple biological materials with a heterogeneous antibody mixture | US09837639 | 2001-04-17 | US06696264B2 | 2004-02-24 | William T. Bodenhamer; George Jackowski; Eric Davies; Mansel Griffiths |
| The present invention relates to bioassay materials useful for the detection of toxic substances and, more particularly, to packaging materials for food and other products, along with methods for their manufacture and use. The invention provides a unique composite material capable of detecting and identifying multiple biological materials within a single package. The biological material identification system is designed for incorporation into existing types of flexible packaging material such as polyvinylchloride or polyolefin films, and its introduction into the existing packaging infrastructure will require little or no change to present systems or procedures. | ||||||
| 124 | Surface binding of an immunoglobulin to a flexible polymer using a water soluble varnish matrix | US09724438 | 2000-11-28 | US06692973B1 | 2004-02-17 | William T. Bodenhamer; George Jackowski; Eric Davies |
| The present invention relates to bioassay materials useful for the detection of toxic substances and, more particularly, to packaging materials for food and other products, along with methods for their manufacture and use. The invention provides a unique composite material capable of detecting and identifying multiple biological materials within a single package. The biological material identification system is designed for incorporation into existing types of flexible packaging material such as polyvinylchloride or polyolefin films, and its introduction into the existing packaging infrastructure will require little or no change to present systems or procedures. | ||||||
| 125 | Biological material detecting articles of manufacture | US10002402 | 2001-10-25 | US20030211635A1 | 2003-11-13 | William T. Bodenhamer; Terri Lander |
| The present invention relates to articles of manufacture inclusive of or in combination with a biological assay material, formed from a material capable of detecting and identifying the presence of one or more particular toxic substances, wherein said toxic substances may comprise a multiplicity of biological materials. | ||||||
| 126 | Formulations of recombinant papillomavirus vaccines | US09331290 | 2000-01-14 | US06280740B1 | 2001-08-28 | Sunil K. Gupta; George E. Mark, III |
| Vaccine formulations comprising recombinant early (E) and late (L) proteins of papillomavirus and oxidized mannan as well as methods of making and using the formulations are provided. | ||||||
| 127 | Method of removing shiga-like toxins from biological samples | US126645 | 1993-09-27 | US5620858A | 1997-04-15 | Glen D. Armstrong; Robert M. Ratcliffe |
| Diagnostic and therapeutic compositions which comprise the .alpha.Gal(1-4).beta.Gal subunit are described. These compositions permit the rapid diagnosis and treatment of enteric infections caused by E. coli that produce shiga-like toxins (SLT). | ||||||
| 128 | IMMUNOLOGICAL DETECTION METHOD AND KIT FOR MYCOPLASMA PNEUMONIAE | EP16743435 | 2016-01-27 | EP3252472A4 | 2018-07-04 | SAITO KENJI |
| The present invention aims at providing a specific antibody that can simply and rapidly detect Mycoplasma pneumoniae which is a causative bacterium of mycoplasma pneumonia, with high sensitivity, and also an immunological detection method and a kit containing the same antibody. The present invention makes it possible to diagnose infection with Mycoplasma pneumoniae more rapidly and specifically than the conventional method, by producing an antibody recognizing a specific epitope of P30 protein of Mycoplasma pneumoniae and performing an immunological detection using the antibody. Also, the present invention enables easy and rapid detection of Mycoplasma pneumoniae and diagnosis of infection with the same at a hospital or the like without need of specialized instruments or skilled techniques. | ||||||
| 129 | IMMUNOLOGICAL DETECTION METHOD AND KIT FOR MYCOPLASMA PNEUMONIAE | EP16743434 | 2016-01-27 | EP3252471A4 | 2018-07-04 | SAITO KENJI |
| The present invention aims at providing a specific antibody that can simply and rapidly detect Mycoplasma pneumoniae which is a causative bacterium of mycoplasma pneumonia, with high sensitivity, and also an immunological detection method and a kit containing the same antibody. The present invention makes it possible to diagnose infection with Mycoplasma pneumoniae more rapidly and specifically than the conventional method, by producing an antibody recognizing a specific epitope of P30 protein of Mycoplasma pneumoniae and performing an immunological detection using the antibody. Also, the present invention enables easy and rapid detection of Mycoplasma pneumoniae and diagnosis of infection with the same at a hospital or the like without need of specialized instruments or skilled techniques. | ||||||
| 130 | AIRBORNE AGENT COLLECTORS, METHODS, SYSTEMS AND DEVICES FOR MONITORING AIRBORNE AGENTS | EP15825205 | 2015-07-21 | EP3185995A4 | 2018-03-28 | KINDT THOMAS; STEEL JOHN |
| Air flow systems, devices and methods for monitoring airborne agents include airborne agent collectors. Airborne agent collectors for collecting and detecting the presence and/or identification of an airborne agent(s) include a soluble and hydrophilic polycaprolactone (PCL) that has been treated with a base (e.g., a base having a pH greater than 8 (e.g., NaOH, NaHCO3, KOH, Na2CO3, and CA(OH)2) and in some embodiments, also treated with a neutralizing agent for increasing hydrophilicity. Detection and identification of airborne agents captured by an airborne agent collector can be performed using any suitable analytical protocols. Such protocols are well known in the art, and include nucleic acid assays, protein assays (e.g., mass spectrometry), and bioassays (e.g., in vitro and in vivo assays). The airborne agent collectors can be used for the detection and identification of nucleic acid from cells or organisms of any type (e.g., viruses, bacteria, fungi) in fixed structures (e.g., homes, sports arenas, theaters, buildings such as offices, laboratories, hospitals, schools, airports, train stations, bus stations, etc.) and in mobile, portable devices or machines (e.g., aircraft, automobiles, air-freshener, air-purifier, air re-circulator, vacuum cleaner, etc.). | ||||||
| 131 | VERFAHREN ZUR VERMINDERUNG DER ADHÄSION VON MIKROORGANISMEN AN TEXTILIEN | EP14824449.4 | 2014-12-18 | EP3084066B1 | 2017-10-25 | KATZENMEIER, Heinz; STUTTE, Peter; SCHMIDT-EMRICH, Sabrina; THÖNY-MEYER, Linda; ZULIAN, Qun Ren |
| 132 | AVIAN REOVIRUS VACCINES | EP15743978 | 2015-01-29 | EP3099789A4 | 2017-09-13 | SELLERS HOLLY S |
| The present invention relates to novel strains of avian reovirus that were isolated from clinical cases of viral arthritis/tenosynovitis in chickens in the southeast United States. The invention is directed to these novel group 1 and group 2 avian reoviruses, diagnostic assays using antibodies and/or nucleotide- or amino acid-specific components of such viruses, such as the S1 gene encoding the sigma C protein, and to vaccines that protect chickens from disease caused by such viruses. | ||||||
| 133 | VERFAHREN ZUR VERMINDERUNG DER ADHÄSION VON MIKROORGANISMEN AN TEXTILIEN | EP14824449.4 | 2014-12-18 | EP3084066A2 | 2016-10-26 | KATZENMEIER, Heinz; STUTTE, Peter; SCHMIDT-EMRICH, Sabrina; THÖNY-MEYER, Linda; ZULIAN, Qun Ren |
| The invention relates to a method for finishing fibers and/or fabrics with the aim of reducing adhesion of microorganisms, in particular bacteria and/or yeasts, to the fibers and/or fabrics. The disclosed method involves applying a composition (ZS) containing selected hydrophilic silane derivatives to the fibers and/or fabrics. The invention further relates to a method for quantitatively determining the adhesion of microorganisms to fibers and/or fabrics. | ||||||
| 134 | ANTIBODIES DIRECTED AGAINST INFLUENZA | EP12841118.8 | 2012-10-18 | EP2768858A2 | 2014-08-27 | AHMED, Rafi; WRAMMERT, Jens; WILSON, Patrick, C. |
| Antibodies that specifically bind influenza virus hemagglutinin A (HA), and antigen binding fragments thereof are disclosed herein. In several embodiments, these antibodies are broadly neutralizing. Nucleic acids encoding these monoclonal antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed. Compositions are disclosed that include these antibodies, antigen binding fragments, nucleic acids, vectors and host cells. Method of using these antibodies, and antigen binding fragments, nucleic acids, vectors and host cells, such as for diagnosis and treatment of an influenza virus infection are also provided. | ||||||
| 135 | DIAGNOSIS AND TREATMENT OF BACTERIAL DYSENTERY. | EP92922817 | 1992-10-19 | EP0610356A4 | 1995-03-29 | ARMSTRONG GLEN D; RATCLIFFE R MURRAY |
| There is provided the use of an agent in the preparation of a medicament for the prevention or treatment of an enteric infection mediated by an SLT, wherein said agent is a pharmaceutically acceptable solid inert affinity support capable of being eliminated from the gastrointestinal tract, which support has an affinity ligand covalently attached thereto through a spacer arm, wherein said ligand is characterized as an oligosaccharide containing the disaccharide subunit alpha Gal(1-4) beta Gal which binds the SLT; with the proviso that the disaccharide is not part of a alpha Gal(1-4) beta Gal(1-4) beta GlcNAc trisaccharide or a alpha Gal(1-4) beta Gal(1-4) beta Glc trisaccharide. | ||||||
| 136 | ANTIBODIES DIRECTED AGAINST INFLUENZA | EP12841118.8 | 2012-10-18 | EP2768858B1 | 2018-08-01 | AHMED, Rafi; WRAMMERT, Jens; WILSON, Patrick, C. |
| Antibodies that specifically bind influenza virus hemagglutinin A (HA), and antigen binding fragments thereof are disclosed herein. In several embodiments, these antibodies are broadly neutralizing. Nucleic acids encoding these monoclonal antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed. Compositions are disclosed that include these antibodies, antigen binding fragments, nucleic acids, vectors and host cells. Method of using these antibodies, and antigen binding fragments, nucleic acids, vectors and host cells, such as for diagnosis and treatment of an influenza virus infection are also provided. | ||||||
| 137 | METAL-ANTIBODY TAGGING AND PLASMA-BASED DETECTION | EP15840345 | 2015-09-14 | EP3191840A4 | 2018-04-11 | ROBINSON JOSEPH PAUL; RAJWA BARTOLOMEJ P; PATSEKIN VALERI P; BAE EUIWON |
| An apparatus and method for characterizing a target, e.g., microbial samples or biological toxins, includes labeling the target with a biomolecular recognition construct and measuring an atomic-spectra signal of the biomolecular recognition construct. The method can include heating the labeled target before measuring the atomic-spectra signal. The atomic-spectra signal can be measured by performing laser-induced breakdown spectroscopy. The atomic-spectra signal can be measured by performing spark induced breakdown spectroscopy. The biomolecular recognition construct can be prepared by tagging a biological scaffolding with a metal atom or ion. In an aspect in which the target includes a microbial sample, the biological scaffolding can include an antibody against epitopes present on bacterial surface, the antibody linked to a heavy metal. In an aspect in which the target includes a biological toxin, the biological scaffolding can include an antibody against the biological toxin linked to heavy metals. | ||||||
| 138 | AVIAN REOVIRUS VACCINES | EP15743978.7 | 2015-01-29 | EP3099789A1 | 2016-12-07 | SELLERS, Holly, S. |
| The present invention relates to novel strains of avian reovirus that were isolated from clinical cases of viral arthritis/tenosynovitis in chickens in the southeast United States. The invention is directed to these novel group 1 and group 2 avian reoviruses, diagnostic assays using antibodies and/or nucleotide- or amino acid-specific components of such viruses, such as the S1 gene encoding the sigma C protein, and to vaccines that protect chickens from disease caused by such viruses. | ||||||
| 139 | COMPOSITIONS CONTAINING COMBINATIONS OF BIOACTIVE MOLECULES DERIVED FROM MICROBIOTA FOR TREATMENT OF DISEASE | EP14822228 | 2014-07-08 | EP3019181A4 | 2016-09-21 | HONDA KENYA; OLLE BERNAT; ATARASHI KOJI; TANOUE TAKESHI; OHNO HIROSHI; FUKUDA SHINJI; HASE KOJI |
| Compositions consisting of bioactive molecules derived from the microbiota of a mammal are provided herein. When administered orally with a colonic delivery system, the compositions are useful for the prophylaxis and treatment of diseases, in particular inflammatory, autoimmune and infectious diseases. The compositions comprise combinations of small molecules and bacterial antigens formulated in colonic delivery systems. Use of the compositions results in any or all of: induction of immune tolerance; strengthening of the gut mucosal barrier integrity; reduction of inflammation; and amelioration of a disease state caused by inflammation, an autoimmune reaction or an infectious agent. | ||||||
| 140 | COMPOSITIONS CONTAINING COMBINATIONS OF BIOACTIVE MOLECULES DERIVED FROM MICROBIOTA FOR TREATMENT OF DISEASE | EP14822228.4 | 2014-07-08 | EP3019181A2 | 2016-05-18 | HONDA, Kenya; OLLE, Bernat; ATARASHI, Koji; TANOUE, Takeshi; OHNO, Hiroshi; FUKUDA, Shinji; HASE, Koji |
| Compositions consisting of bioactive molecules derived from the microbiota of a mammal are provided herein. When administered orally with a colonic delivery system, the compositions are useful for the prophylaxis and treatment of diseases, in particular inflammatory, autoimmune and infectious diseases. The compositions comprise combinations of small molecules and bacterial antigens formulated in colonic delivery systems. Use of the compositions results in any or all of: induction of immune tolerance; strengthening of the gut mucosal barrier integrity; reduction of inflammation; and amelioration of a disease state caused by inflammation, an autoimmune reaction or an infectious agent. | ||||||
QQ群二维码
意见反馈
意见反馈